Snap rebounds again, up 12% in a week >>> READ MORE

IPOs: The 5 Best New Stocks of Q1 2014

Pharmaceutical companies dominate the list of best IPOs


Best New Stocks — Dicerna Pharmaceuticals (DRNA)

new-stocks-iposIPO Return: 146.5%

Dicerna Pharmaceuticals (DRNA) is a biotech company that focuses on treatments for rare inherited diseases, such as for those affecting the liver or for cancers. To do this, company has developed a proprietary RNA interference (RNAi) platform. This year, it plans to begin clinical trials of its lead candidate.

In terms of the go-to-market strategy, Dicerna has a two-pronged approach. For rare-disease drugs, the company will put together a small sales force. Keep in mind that these types of treatments get government subsidies.

As for the oncology drugs, Dicerna will rely on a partnership strategy. And yes, the company already has a major partner, Kyowa Hakko Kirin.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC